Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tafamidis Free Acid Tablet vs Commercial Capsule in Healthy Subjects
NCT02697864Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (3 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time Curve at 120 hours and Maximum Observed Plasma Concentration at 120 hours. Started Apr 2016; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT02697864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697864.